Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICI) are now standard-of-care treatment for patients with metastatic gastric cancer (GC). To guide patient selection for ICI therapy, programmed death ligand-1 (PD-L1) biomarker expression is routinely assessed via immunohistochemistry (IHC). However, with an increasing number of approved ICIs, each paired with a different PD-L1 antibody IHC assay used in their respective landmark trials, there is an unmet clinical and logistical need for harmonization. We investigated the interchangeability between the Dako 22C3, Dako 28-8 and Ventana SP-142 assays in GC PD-L1 IHC.

Methods

In this cross-sectional study, we scored 362 GC samples for PD-L1 combined positive score (CPS), tumor proportion score (TPS) and immune cells (IC) using a multipl

SUBMITTER: Yeong J 

PROVIDER: S-EPMC9226082 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature